Tariff-based cost estimates raise questions around robotic knee replacement economics
A BMJ rapid response has challenged the cost inputs used to assess robotic knee replacement, arguing that the economic assumptions behind the comparison with conventional surgery may be built on prices rather than true health-system costs. The critique lands at the center of a policy debate over whether NHS expansion of robotic arthroplasty is justified by the balance of expense, revision avoidance, and long-term value.
The response focuses on two figures used in the original analysis: an estimated £16,000 cost for a knee revision and an added robotic surgery cost of roughly £1,000 to £2,500 per knee. Both numbers trace back to the same 2023/24 self-pay tariff from Wrightington, Wigan and Leigh NHS Foundation Trust. The revision estimate is close to the tariff at £15,872, but the robotic estimate does not line up cleanly with the tariff structure. Within that tariff, a standard knee replacement is priced at £10,500 and a robotic one at £14,000, a difference of £3,500 rather than the smaller increment used in the paper.
A single tariff is not the same thing as the resource cost of care.
The distinction matters because a tariff reflects what a trust decides to charge a private patient for a bundled package, not necessarily what the NHS spends on theatre time, implants, staff, bed occupancy, imaging, rehabilitation, follow-up, or the capital burden of the robot itself. NICE’s reference case values resources at NHS and personal social services costs for exactly that reason. When a tariff is lifted into an economic argument without a full breakdown, it becomes difficult to know whether the estimate captures direct postoperative care, indirect costs, or any share of equipment acquisition and maintenance.
The rapid response also points to the limits of using a single figure as evidence of cost structure. Because the tariff is presented as one amount, it cannot show which components are included or excluded. That leaves an important gap for commissioners who need to decide whether robotic surgery offers value once the NHS procurement environment, staffing model, and capital costs are taken into account.
Revision avoidance may save less than the headline numbers suggest
The response goes further by testing the economic claim in the most favorable scenario for robotics: a setting in which the robot prevents every revision in the first five years. Using the paper’s own inputs, about 1.5% of knees are revised and each revision costs £16,000. On that basis, the avoided revision cost works out to roughly £240 per patient. The calculation is undiscounted, counts first revisions only, and does not establish cost-effectiveness on its own.
That arithmetic matters because revision surgery is expensive, but it is also relatively uncommon over short follow-up periods. If the up-front premium for robotics exceeds the expected savings from avoided revisions, the financial case depends on longer-term durability, better function, fewer complications, or lower downstream use of hospital resources. None of those elements can be inferred from a tariff alone. The economics of joint replacement are sensitive to the inputs chosen, and small changes in revision rate, implant price, or theatre efficiency can shift the conclusion materially.
Why NHS costing standards require a different evidence base
The critique also draws attention to the difference between private tariffs and NHS reference costing. NICE guidance directs analysts to use NHS and personal social services resource costs rather than market prices because the aim is to estimate opportunity cost within the publicly funded system. A tariff built for self-pay activity may reflect commercial packaging, margin, and local pricing strategy. It can still be a useful reference point, but it should not be treated as a direct substitute for resource valuation.
For robotic arthroplasty, that distinction is especially important. Robotic platforms are associated with upfront capital expenditure, maintenance contracts, training, and possible workflow effects in operating theatres. Those costs do not disappear when a procedure is priced as a single package. If the paper’s robotic increment was derived from a private tariff, commissioners are left without clarity on whether the figure includes the robot’s capital share, whether it captures incremental consumables, or whether any downstream savings were built into the estimate.
Direct linkage to registry data creates a route to full economic evaluation
The rapid response ends by pointing to a more rigorous path already available through the same research group’s registry linkage work. The National Joint Registry has previously been linked to Hospital Episode Statistics and patient-reported outcomes, creating the infrastructure needed for a fuller economic evaluation. That would allow NHS resource costs to be layered onto observed outcomes, rather than relying on external tariffs that were never designed to answer the same question.
Such an analysis would not settle every policy issue, but it would move the debate from tariff-based approximation to system-based costing. For robotic knee replacement, where the clinical promise must be weighed against the cost of technology adoption, that shift is central. The central unresolved issue is not whether robotic surgery can be priced; it is whether the price used in the economic model truly reflects what the NHS spends, and whether the savings from fewer revisions or other benefits are large enough to offset the extra investment.
The response also implicitly narrows the policy argument. If commissioners are deciding whether to expand robotic surgery, they need estimates grounded in NHS accounting, not in private self-pay bundles that may bundle together heterogeneous components. Without that, the economic conclusion remains vulnerable to the choice of tariff rather than the reality of service delivery.